Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond. Garitaonaindia Y, Petersen SK, Guldbrandt LM, Borch TH, et al. Int J Cancer 2026 Apr 28. doi: 10.1002/ijc.70520.

Read + Share

Amedeo Smart

Independent Medical Education

Garitaonaindia Y, Petersen SK, Guldbrandt LM, Borch TH, et al. Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond. Int J Cancer 2026 Apr 28. doi: 10.1002/ijc.70520.
PMID: 42050807